{"disease":{"id":"chronic-graft-versus-host-disease","name":"Chronic graft-versus-host disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"ibrutinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"ruxolitinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"axatilimab","indication_name":"chronic graft-versus-host disease (cGVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niktimvo","generic_name":"AXATILIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Colony Stimulating Factor-1 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues."},{"drug_id":"belumosudil","indication_name":"Chronic graft-versus-host disease (chronic GVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezurock","generic_name":"BELUMOSUDIL","company_name":"Kadmon Pharms Llc","drug_phase":"marketed","molecular_target":"Rho-associated protein kinase 1","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rezurock works by inhibiting the Rho-associated protein kinase 1 enzyme, which plays a key role in inflammation and immune response."},{"drug_id":"imbruvica","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00128973","title":"Evaluation of Patients With Immune Function Abnormalities","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05355675","title":"The Association of Microbiota Composition With cGVHD After Allo-HSCT","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT04431479","title":"Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06143891","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02991846","title":"A Prospective Observational Study for Evaluating CGVHD","phase":"","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Gruppo Italiano Trapianto di Midollo Osseo","has_results":false},{"nct_id":"NCT06585774","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03557749","title":"Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies","phase":"","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT02959944","title":"Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Pharmacyclics LLC.","has_results":true},{"nct_id":"NCT03190733","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":192,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT03640481","title":"Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Kadmon, a Sanofi Company","has_results":true},{"nct_id":"NCT03584516","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04692376","title":"MSC for Treatment of cGVHD After Allo-HSCT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":152,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06388564","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05690971","title":"Psychosocial Mobile App for Chronic Graft-Versus-Host Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02743351","title":"Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Fate Therapeutics","has_results":true},{"nct_id":"NCT04189432","title":"Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"SCM Lifescience Co., LTD.","has_results":false},{"nct_id":"NCT05996627","title":"Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":82,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04202835","title":"ATG Plus PTCy vs ATG for CGVHD Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT02701634","title":"Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05873907","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07124078","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03790332","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Pharmacyclics LLC.","has_results":false},{"nct_id":"NCT01954979","title":"Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT04198922","title":"Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02513498","title":"Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07011810","title":"Axatilimab for Sclerotic Chronic Graft-versus-Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06663722","title":"Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT07535008","title":"Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05922761","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04944043","title":"A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03842696","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT03604692","title":"A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":true},{"nct_id":"NCT06271616","title":"Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03128359","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT07116031","title":"A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05236062","title":"Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06815003","title":"Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03192397","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03990051","title":"Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Glia, LLC","has_results":true},{"nct_id":"NCT03422627","title":"Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06843408","title":"A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06233110","title":"Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Stefanie Sarantopoulos, MD, PhD.","has_results":false},{"nct_id":"NCT04540133","title":"Dexamethasone Solution and Dexamethasone in Mucolox™","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04716075","title":"Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Polish Lymphoma Research Group","has_results":false},{"nct_id":"NCT05993611","title":"Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":27,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07135973","title":"A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT00656058","title":"Montelukast to Treat Bronchiolitis Obliterans","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06046248","title":"Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Northside Hospital, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}